Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

QUIDEL

Develops, manufactures and markets rapid diagnostic tests at the point-ofcare (POC) that focus on infectious diseases... read more Featured Products: More products

Download Mobile App





Ortho Exhibits High Quality, Accurate and Cost Effective COVID19 Testing Solutions at AACC 2021

By LabMedica International staff writers
Posted on 28 Sep 2021

Ortho Clinical Diagnostics (Raritan, NJ, USA) exhibited its range of high quality, accurate and cost effective COVID19 testing solutions at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo held at the Georgia World Congress Center in Atlanta, September 26-30.

Over the span of the four day event, attendees connected with global leaders in clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, lab management, and other areas of breaking science in laboratory medicine.

Ortho has been at the forefront of developing high quality, accurate, cost effective COVID19 testing solutions that run at high volumes. At AACC 2021, Ortho demonstrated its high-throughput testing solutions for SARS-CoV-2 infection, antibody detection and antigen detection. These included the high-throughput, highly accurate VITROS SARS-CoV-2 antigen test that detects acute infection of SARS-CoV-2. The test delivers fast, high-volume testing for active infection with excellent specificity and sensitivity, making it a viable alternative to PCR testing.

In addition, Ortho highlighted its three qualitative antibody tests, including the VITROS COVID-19 Total and IgG antibody assays that provide highly accurate and reliable detection of SARS-CoV-2 antibodies to help clinicians and researchers understand immune response; and its VITROS Anti-SARS-CoV-2 Total N antibody test that is designed to capture total antibodies to the nucleocapsid protein. Also on display at AACC 2021 was the VITROS Anti-SARS-CoV-2 IgG quantitative test that helps labs to quantify the level of COVID-19 antibodies for patients and individuals in their communities. The VITROS Anti-SARS-CoV-2 IgG quantitative test is the first quantitative test to receive U.S. Food and Drug Administration (FDA) EUA. Ortho also demonstrated its VITROS Performance Dashboard that allows labs to view productivity data from Ortho analyzers including: test volumes, positivity rates, quality and efficiency information to help make more informed decisions for the hospital and community.

Related Links:
Ortho Clinical Diagnostics 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








ADLM

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.